We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


American CryoStem Awarded Patent for Cell Culture Media

Want a FREE PDF version of this news story?

Complete the form below and we will email you a PDF version of "American CryoStem Awarded Patent for Cell Culture Media"

Listen with
Register for free to listen to this article
Thank you. Listen to this article using the player above.
Read time:

American CryoStem Corporation has announced the grant to it of a patent by the United States Patent Office (USPTO).

American CryoStem Corporation has been awarded U.S. Patent Number 7,989,205, entitled "Cell Culture Media, Kits, and Methods of Use" (the "Patent"), by the USPTO. This Patent covers a unique product for cellular growth in the processing of adult stem cells. This is significant to the Company for the advancement of its research, clinical and cosmetic applications.

The Company's management believes that the Patent will support the Company's efforts in its goal to establish itself as a leader in the preparation of autologous stem cells for use in regenerative medicine.

The Patent includes a specific human formulation to overcome the concerns and issues prevalent in the FDA's and other regulatory agencies' guidance when using non-human biologic materials in the preparation of stem cells for human use.

John S Arnone, CEO, stated, "We are pleased to have the Patent granted to the Company by the USPTO. We believe the Patent will be instrumental to the industry based on its cellular growth properties and absence of non-human biologic material. Further, as stem cell and regenerative medicine advances in the United States, as it has globally, the Company is confident the Patent, together with our core technology and our intellectual property regarding methods, formulations, devices and products will allow us to enter into additional partnerships and collaborations with other industry participants. The Patent validates our corporate direction and enhances our strategy to obtain strong intellectual property protection."

Anthony Dudzinski, COO, stated, "We believe the Patent on specie specific media gives the Company a unique market position by alleviating the significant regulatory requirements associated with products containing fetal bovine serum or other non-human biologic components. The Patent is important and will accelerate the development and commercialization of additional Company products and services. We are excited and very optimistic regarding our place in the stem cell industry and the value of our products and services."